Cargando…
Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma
Advances in the molecular biology of medulloblastoma revealed four genetically and clinically distinct subgroups. Group 3 medulloblastomas are characterized by frequent amplifications of the oncogene MYC, a high incidence of metastasis, and poor prognosis despite aggressive therapy. We investigated...
Autores principales: | Faria, Claudia C., Agnihotri, Sameer, Mack, Stephen C., Golbourn, Brian J., Diaz, Roberto J., Olsen, Samantha, Bryant, Melissa, Bebenek, Matthew, Wang, Xin, Bertrand, Kelsey C., Kushida, Michelle, Head, Renee, Clark, Ian, Dirks, Peter, Smith, Christian A., Taylor, Michael D., Rutka, James T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673298/ https://www.ncbi.nlm.nih.gov/pubmed/26061748 |
Ejemplares similares
-
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
por: Bertrand, Kelsey C., et al.
Publicado: (2018) -
Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
por: Diaz, Roberto Jose, et al.
Publicado: (2014) -
Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway
por: Park, Jun-Bum, et al.
Publicado: (2014) -
Antitumor activity of cyclin‐dependent kinase inhibitor alsterpaullone in Epstein‐Barr virus‐associated lymphoproliferative disorders
por: Watanabe, Takahiro, et al.
Publicado: (2019) -
DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS
por: Stanton, Ann-Catherine, et al.
Publicado: (2020)